Literature DB >> 3142828

Prognostic factors for radiation treatment of mast cell tumor in 85 dogs.

J M Turrel1, B E Kitchell, L M Miller, A Théon.   

Abstract

Ninety-five mast cell tumors in 85 dogs were therapeutically irradiated. Median and mean tumor-free times for dogs were 17 and 62.7 months, respectively. Percentages of dogs tumor-free at 1 and 2 years were 78.8 and 77%, respectively. Factors significantly affecting tumor-free time were clinical stage (P less than 0.001) and neoplasm location (P = 0.019). Median and mean survival times were 19 and 61.2 months, respectively. Survival rates at 1 and 2 years were 76.2 and 73.2%, respectively. Prognostic factors that significantly affected survival rates were clinical stage (P less than 0.001), neoplasm grade (P = 0.006), and neoplasm location (P = 0.034). Radiation therapy was an effective treatment of mast cell tumor in dogs.

Entities:  

Mesh:

Year:  1988        PMID: 3142828

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  8 in total

1.  Nasal-skin-fold transposition flap for upper lip reconstruction in a French bulldog.

Authors:  Manuel Benlloch-Gonzalez; Stéphanie Lafarge; Bernard Bouvy; Cyrill Poncet
Journal:  Can Vet J       Date:  2013-10       Impact factor: 1.008

2.  Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.

Authors:  C Robat; C London; L Bunting; L McCartan; N Stingle; K Selting; I Kurzman; D M Vail
Journal:  Vet Comp Oncol       Date:  2011-01-31       Impact factor: 2.613

3.  Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors.

Authors:  K S Carlsten; C A London; S Haney; R Burnett; A C Avery; D H Thamm
Journal:  J Vet Intern Med       Date:  2011-12-19       Impact factor: 3.333

4.  Aggressive local therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumour: 21 cases (1999-2012).

Authors:  A Lejeune; K Skorupski; S Frazier; I Vanhaezebrouck; R B Rebhun; C M Reilly; C O Rodriguez
Journal:  Vet Comp Oncol       Date:  2013-05-31       Impact factor: 2.613

Review 5.  Diagnosis, Prognosis and Treatment of Canine Cutaneous and Subcutaneous Mast Cell Tumors.

Authors:  Andrigo Barboza de Nardi; Rodrigo Dos Santos Horta; Carlos Eduardo Fonseca-Alves; Felipe Noleto de Paiva; Laís Calazans Menescal Linhares; Bruna Fernanda Firmo; Felipe Augusto Ruiz Sueiro; Krishna Duro de Oliveira; Silvia Vanessa Lourenço; Ricardo De Francisco Strefezzi; Carlos Henrique Maciel Brunner; Marcelo Monte Mor Rangel; Paulo Cesar Jark; Jorge Luiz Costa Castro; Rodrigo Ubukata; Karen Batschinski; Renata Afonso Sobral; Natália Oyafuso da Cruz; Adriana Tomoko Nishiya; Simone Crestoni Fernandes; Simone Carvalho Dos Santos Cunha; Daniel Guimarães Gerardi; Guilherme Sellera Godoy Challoub; Luiz Roberto Biondi; Renee Laufer-Amorim; Paulo Ricardo de Oliveira Paes; Gleidice Eunice Lavalle; Rafael Ricardo Huppes; Fabrizio Grandi; Carmen Helena de Carvalho Vasconcellos; Denner Santos Dos Anjos; Ângela Cristina Malheiros Luzo; Julia Maria Matera; Miluse Vozdova; Maria Lucia Zaidan Dagli
Journal:  Cells       Date:  2022-02-10       Impact factor: 6.600

6.  Tolerability and Effects of 2-Aminoethyl Dihydrogen Phosphate in Dogs With Mast Cell Tumors.

Authors:  Eric Vieira Januário; Samanta Rios Melo; Durvanei Augusto Maria; Carla Aparecida Batista Lorigados; Aline Magalhães Ambrósio; Marcia Mery Kogika; Bruno Cogliati; Helio Junji Shimozako; Julia Maria Matera
Journal:  Front Vet Sci       Date:  2022-07-12

7.  Autologous blood pleurodesis for surgical pneumothorax and outcome with multimodal cancer treatment in a dog with primary pulmonary mast cell tumor.

Authors:  Daniel Shinsako; Alison R Masyr; Miranda Vieson; Hadley E Gleason
Journal:  Clin Case Rep       Date:  2022-07-25

8.  A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs.

Authors:  Laura E Selmic; Audrey Ruple
Journal:  BMC Vet Res       Date:  2020-01-06       Impact factor: 2.741

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.